. . . "Reijo Toivola, Tuomas Huuhtanen, \"Toremifene crystallization method.\" U.S. Patent US20070093556, issued April 26, 2007."@en . . . . . "Humans and other mammals"@en . . . . "89778-26-7"@en . . " "@en . . . "Toremifen is primarily bound to albumin (92%), 2% bound to \u03B11-acid glycoprotein, and 6% bound to \u03B21-globulin in the serum."@en . . . "Well absorbed"@en . . . . "Toremifene is a nonsteroidal triphenylethylene derivative. Toremifene binds to estrogen receptors and may exert estrogenic, antiestrogenic, or both activities, depending upon the duration of treatment, animal species, gender, target organ, or endpoint selected. The antitumor effect of toremifene in breast cancer is believed to be mainly due to its antiestrogenic effects, in other words, its ability to compete with estrogen for binding sites in the cancer, blocking the growth-stimulating effects of estrogen in the tumor. Toremifene may also inhibit tumor growth through other mechanisms, such as induction of apoptosis, regulation of oncogene expression, and growth factors."@en . "* 5 L/h"@en . . . "Toremifene is extensively metabolized, principally by CYP3A4 to N-demethyltoremifene, which is also antiestrogenic but with weak in vivo antitumor potency."@en . . . "5 days"@en . "Toremifenum"@en . . . . . . . . . . . "* 580 L"@en . . . . . "approved"@en . . . "# Price N, Sartor O, Hutson T, Mariani S: Role of 5a-reductase inhibitors and selective estrogen receptor modulators as potential chemopreventive agents for prostate cancer. Clin Prostate Cancer. 2005 Mar;3(4):211-4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15882476 # Taneja SS, Smith MR, Dalton JT, Raghow S, Barnette G, Steiner M, Veverka KA: Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. Expert Opin Investig Drugs. 2006 Mar;15(3):293-305. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16503765 # Thompson IM: Chemoprevention of prostate cancer: agents and study designs. J Urol. 2007 Sep;178(3 Pt 2):S9-S13. Epub 2007 Jul 20. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17644117 # Ariazi EA, Ariazi JL, Cordera F, Jordan VC: Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem. 2006;6(3):181-202. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16515478 # Musa MA, Khan MO, Cooperwood JS: Medicinal chemistry and emerging strategies applied to the development of selective estrogen receptor modulators (SERMs). Curr Med Chem. 2007;14(11):1249-61. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17504144"@en . . "investigational"@en . . . . . "For the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or receptor-unknown tumors. Toremifene is currently under investigation as a preventative agent for prostate cancer in men with high-grade prostatic intraepithelial neoplasia and no evidence of prostate cancer."@en . . . "A first generation nonsteroidal selective estrogen receptor modulator (SERM) that is structurally related to tamoxifen. Like tamoxifen, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue. [PubChem]"@en . . "Toremifeno"@en . "Toremifene"@en . .